AstraTATE is a groundbreaking Danish research and innovation project aiming to develop a next-generation alpha radionuclide therapy for neuroendocrine tumors (NETs), a rare and often late-diagnosed cancer with limited treatment options. With a DKK 21.7 million investment from Innovation Fund Denmark, the consortium is harnessing the combined strengths of Denmark’s leading institutions and biotech innovators to bring this therapy from lab to clinic.

At the heart of AstraTATE is astatine-211 (²¹¹At), a powerful alpha-emitting radionuclide with the potential to eliminate tumors while sparing healthy tissue. The project addresses long-standing challenges in ²¹¹At -based therapy through a uniquely qualified group of partners:

Rigshospitalet houses Europe’s only clinical-grade ²¹¹At production facility, with over 25 years of experience in radiochemistry. It ensures a reliable supply of the radiohalogen needed for therapy development.

TetraKit Technologies contributes its patented radiolabeling platform, enabling fast, stable, and efficient binding of ²¹¹At to cancer-targeting molecules. This platform is central to producing a safe, effective therapeutic compound.

The Department of Drug Design and Pharmacology at the University of Copenhagen brings deep radiochemical and pharmacological expertise, responsible for designing the ²¹¹At-labeled drug to selectively target tumor cells.

Cluster for Molecular Imaging (UCPH) provides advanced preclinical tumor models, especially for NETs, and extensive experience in evaluating theranostic treatments in vivo.

Minerva Imaging, a leading European CRO/CDMO in translational oncology, is in charge of translating the therapy from preclinical stages to clinical readiness, ensuring regulatory and production scalability.

Together, the AstraTATE consortium is positioned to deliver a first-of-its-kind alpha therapy for NETs, combining deep academic expertise, cutting-edge biotech innovation, and clinical infrastructure to set a new standard in precision cancer treatment.